Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Adherence news

Show

From To
Should Gilead Be Worried About This New Monthly HIV Medication?

Yesterday, Johnson & Johnson and ViiV Healthcare announced positive results from the Atlas phase 3 study testing their two-drug HIV treatment containing an investigational drug cabotegravir and rilpivirine, a nucleoside reverse transcriptase inhibitor (NRTI) sold by Johnson & Johnson as Edurant. The important thing here isn't going from three medications to two, but that ViiV and Johnson & Johnson's cabotegravir and rilpivirine combination is injected once a month compared to a daily therapy for the three-drug combination.

Published
16 August 2018
From
Motley Fool
HIV drug research in Wales to cut infection risk

Nearly 400 people have been taking part in a three-year trial of the drugs in Wales since last summer. Cardiff University will now examine how people have been taking the medicine - and if that affects the protection.

Published
16 August 2018
From
BBC
TAC: ARV treatment education best way to bring down HIV infection rates

An activist organisation, the Treatment Action Campaign (TAC), says that for South Africa to further decrease the rate of new HIV infections more needs to be done to curb treatment defaulting for persons on the ARV treatment programme.

Published
18 July 2018
From
Eyewitness News
Blood, Hair, or Urine? Weighing PrEP Adherence Options Beyond Self-Report

Understanding whether a person with a PrEP prescription is actually using the medication is something a provider may want to know. Currently, a few measures determine adherence to PrEP: self-report, hair, dried blood spot, and urine analysis. As of now, no one guideline or definitive standard is being used. Clinicians and researchers presented their recent findings at the 13th Annual Adherence Conference last month in Miami.

Published
16 July 2018
From
The Body Pro
'Emotional closeness’ key to successful HIV treatment support

The type of relationship someone living with HIV has with both their social network and a nominated ‘treatment partner’ is likely to influence whether they are virally suppressed, research from Botswana suggests.

Published
15 June 2018
From
AVERT
Is the World Ready for Long-Acting HIV Treatment?

"As we look at this question [of] where do long-acting antiretrovirals fit into the armamentarium," commented Carl Dieffenbach, the director of the Division of AIDS within the National Institute of Allergy and Infectious Diseases, "we have to ask ourselves the question: What problems are long-acting or sustained-release formulations solving, and what problems or concerns are the introduction of these type of formulations actually creating?"

Published
11 June 2018
From
The Body Pro
Short Cycle ART Noninferior to Continuous Therapy in Youth With HIV

Short cycle therapy (SCT) comprising an antiretroviral therapy (ART) regime of 5 days on and 2 off achieved sustainable noninferiority of virological suppression in young people with HIV compared with continuous therapy (CT) over a median of 3.6 years, according to research published in PLos One.

Published
25 May 2018
From
Infectious Disease Advisor
Smartphone app keeps an 'eye' on daily tuberculosis therapy

Johns Hopkins researchers report success with a smart phone video-based app that substitutes for a daily in-person visit by a health care worker required for tuberculosis treatment known as directly observed therapy, or DOT. The preliminary study showed that the app may be less costly and may improve privacy concerns raised by patients compared to in-person visits.

Published
27 April 2018
From
Eurekalert Inf Dis
Has Anyone Gotten HIV When They Were on PrEP?

At least 300,000 individuals are now using PrEP worldwide, and only two incidents have been reported where individuals with verified adherence to the drug acquired HIV. Three additional cases have been reported with unconfirmed adherence, and three are currently under investigation.

Published
22 April 2018
From
The Body
Uganda:HIV Patients to Get Rewards for Taking ARVs

Mildmay Uganda and the United States based RAND Corporation yesterday launched a five-year research study of rewarding people living with HIV who take their antiretroviral drugs consistently.

Published
20 April 2018
From
AllAfrica
← First12345...41Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.